XML 64 R51.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Revenue Recognition (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Apr. 30, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Jun. 30, 2015
Revenue Recognition [Line Items] |  |  |  |  |  |
Revenue, Net, Total |  | $ 448,000 | $ 7,000 | $ 914,000 | $ 13,000 |
License and Maintenance Revenue |  |  |  | 21,000 | $ 43,000 |
Vyrix Pharmaceuticals Inc [Member] |  |  |  |  |  |
Revenue Recognition [Line Items] |  |  |  |  |  |
Deferred Revenue | $ 250,000 |  |  |  |  |
Deferred Revenue Recognition Period | 7 years |  |  |  |  |
Potential Milestone Payments Receivable | $ 3,025,000 |  |  |  |  |
Agreement Expiration Period | 15 years |  |  |  |  |
KOREA | Korean Pharmaceutical Company [Member] |  |  |  |  |  |
Revenue Recognition [Line Items] |  |  |  |  |  |
Deferred Revenue |  | 500,000 |  | $ 500,000 |  |
Deferred Revenue Recognition Period |  |  |  | 10 years | 10 years |
KOREA | Ampio [Member] |  |  |  |  |  |
Revenue Recognition [Line Items] |  |  |  |  |  |
Deferred Revenue |  |  |  |  |  | $ 500,000
Deferred Revenue Recognition Period |  |  |  |  |  | 10 years
Proceeds from License Fees Received |  |  |  |  |  | $ 418,000
Potential Milestone Payments Receivable |  |  |  |  |  | $ 3,200,000
Percentage Of Royalty Rate Of Net Sales |  |  |  |  |  | 25.00%
CANADA | Canadian Based Supplier [Member] |  |  |  |  |  |
Revenue Recognition [Line Items] |  |  |  |  |  |
Deferred Revenue |  | $ 250,000 |  | $ 250,000 |  |
Deferred Revenue Recognition Period |  |  |  | 7 years | 7 years |

X
- Definition Agreement expiration period. + References No definition available. + Details
Name: | aytu_AgreementExpirationPeriod
Namespace Prefix: | aytu_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Deferred revenue recognition period. + References No definition available. + Details
Name: | aytu_DeferredRevenueRecognitionPeriod
Namespace Prefix: | aytu_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalty rate of net sales. + References No definition available. + Details
Name: | aytu_PercentageOfRoyaltyRateOfNetSales
Namespace Prefix: | aytu_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential milestone payments receivable. + References No definition available. + Details
Name: | aytu_PotentialMilestonePaymentsReceivable
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | aytu_RevenueRecognitionLineItems
Namespace Prefix: | aytu_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue from multiple-deliverable arrangements that include licensing fees and maintenance revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Maintenance revenue is derived from maintenance services provided under contracts or arrangements with clients. Services may include the maintenance of software, plant and equipment, and facilities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(d),(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_LicenseAndMaintenanceRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received from licensees for license fees during the current period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_SalesRevenueNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | dei_LegalEntityAxis=aytu_VyrixPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_KR
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=aytu_KoreanPharmaceuticalCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=aytu_AmpioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_CA
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=aytu_CanadianBasedSupplierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |